Antibody-based therapeutics

#Antibody-based therapeutics #Canada #Non-animal model (NAM)

Canadian companies to partner on novel antibody therapies 

VoxCell BioInnovation and adMare BioInnovations have announced a research partnership to advance novel antibody therapies in non-animal models.  VoxCell says its human-relevant vascularised tissue platform brings together human tumour, immune, and stromal compartments alongside a perfused, endothelial-lined vasculature in a single bioprinted construct.   The result is a… Read More

#News

Therapeutic antibodies
#Absci #AI #AI / data analytics / healthtech / informatics #Antibody-based therapeutics #Biologics #Generative AI #Machine learning

How the next generation of AI is reshaping antibody drug discovery

This is the latest episode of the free DDW Narrated Podcast. The episode covers two articles written for DDW Volume 25, Issue 2, Spring 2024. The first article is called ‘Machine learning: developing next generation antibody therapeutics’. Ben Holland, CTO and Co-Founder of Antiverse, discusses how artificial intelligence and… Read More

#Featured Podcasts #Podcasts

#Antibody-based therapeutics #Interview #Lyme Disease #Monoclonal antibodies #Tonix Pharmaceuticals

Is monoclonal antibody prophylaxis the answer to the growing threat of Lyme?

Diana Turner catches up with Seth Lederman, Co-Founder, CEO and Chairman of Tonix Pharmaceuticals, about the company’s new preventative monoclonal antibody therapy for Lyme disease.  DT: For anyone who hasn’t come across the disease before, what is Lyme disease and how is it contracted? SL: Lyme disease is a tick‑borne… Read More

#Exclusive Content

Urticaria or hives
#Antibody-based therapeutics #Atopic dermatitis

UCB publishes new data on clinical trials for galvokimig

Global biopharmaceutical company UCB has announced new 12-week efficacy and 18-week safety data from the Phase I/IIa first-in-patient trial for galvokimig, investigating treatment for atopic dermatitis (AD).  Galvokimig, a novel multi-specific antibody-based therapeutic, is currently under clinical investigation for adults living with moderate-to severe cases of AD. Read More

#News

Female researcher in a laboratory
#Antibiotic resistance #Antibiotics #Antibody-based therapeutics #Antimicrobial resistance (AMR) #Cancer research #Carbon emissions #Environmental impact #Green lab movement #Immunotherapy #Interview #Lab technology #Molecular Biology #Oncology #Sustain #T cell activation

New podcast: Strategies and challenges in drug discovery

This is the latest episode of the free DDW narrated podcast, titled “Strategies and challenges in therapeutic development and lab practice”, which covers three articles written for DDW Volume 24 – Issue 4, Fall 2023. They are called: “The inner workings of antibiotics”, “Targeting advances in immunotherapies”, and… Read More

#News

Artificial intelligence
#AI / data analytics / healthtech / informatics #Antibodies #Antibody-based therapeutics #Artificial intelligence (AI) #Clinical trial design #Clinical trials #Start-ups

New podcast: Innovative applications of AI in drug discovery

This is the latest episode of the free DDW narrated podcast, titled “Innovative applications of AI in drug discovery”, which covers two articles written for DDW Volume 24 – Issue 4, Fall 2023. They are called: “Decoding diseases: The AI renaissance in clinical trials” and “Advancing antibody… Read More

#News

#Antibody engineering #Antibody-based therapeutics #eBook #Monoclonal antibodies #Therapeutic Antibodies

eBook: The significance of mAbs in drug discovery and development

Monoclonal antibodies (mAbs), thanks to their low toxicity and high specificity, have enjoyed incredible market success across a range of disease categories. Of the 2024 top 10 bestselling drugs, half were mAbs, with Merck’s Keytruda (pembrolizumab) in the lead, followed by Abbvie’s Humira (adalimumab), Sanofi and… Read More

#News

#Antibody-based therapeutics #Immunotherapy #Monoclonal antibodies #Oncology

New DDW Highlights episode: 30 September 2024

The latest episode of the DDW Highlights podcast is now available to listen to and watch below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates. The publication of DDW’s latest eBook on immunotherapy has coincided… Read More

#News

#Antibody-based therapeutics #Immunotherapy #Monoclonal antibodies #Oncology

This week in drug discovery (23-27 September) 

News round-up for 23-27 September by DDW Senior Digital Content Editor Diana Spencer. The publication of DDW’s latest eBook on immunotherapy has coincided with some interesting developments in this therapy area, particularly monoclonal antibodies, including two new regulatory approvals. The top stories: Innovent… Read More

#News

#Antibody-based therapeutics #Fibrosis #Lung disease #Mediar Therapeutics #Phase I trial

Phase I IgG1 antibody treatment could halt fibrosis

The first cohort of participants has been dosed in a Phase I trial MTX-474, a human IgG1 antibody designed to neutralise EphrinB2 signalling to treat fibrosis. The study, taking place in Australia, is designed to assess the safety, tolerability, pharmacokinetics, and target engagement of MTX-474 in… Read More

#News

#AI / data analytics / healthtech / informatics #Antibody-based therapeutics #Artificial intelligence (AI) #Machine learning

Machine learning: Developing next generation antibody therapeutics

Ben Holland, CTO and Co-Founder of Antiverse, discusses how artificial intelligence and machine learning are benefitting antibody discovery and design. Modern experimental procedures, such as immunisation, B-cell screening, and synthetic library generation, have been pivotal in developing approximately 80 FDA-approved antibody therapeutics. This remarkable progress in antibody modalities for disease… Read More

#Exclusive Content

Human antibodies
#Antibodies #Antibody discovery workflow #Antibody-based therapeutics #Monoclonal antibodies #Therapeutic Antibodies

Opportunity in the antibody market: Hear from the experts

Join DDW for this free event ‘Where is the opportunity in the therapeutic antibody market?’, which is co-sponsored by Bio-Rad and Benchling. The event will take place on 30 April at 3PM BST / 4pm CEST / 10am EDT / 7am PDT. Read More

Webinar date:
Co-sponsored by Benching and Bio-Rad
#News

Monoclonal antibodies
#Antibodies #Antibody discovery workflow #Antibody-based therapeutics #Monoclonal antibodies #Therapeutic Antibodies

Webinar: How can we develop better therapeutic antibodies?

Join DDW for this free event ‘Where is the opportunity in the therapeutic antibody market?’, which is co-sponsored by Bio-Rad and Benchling. The event will take place on 30 April at 3PM BST / 4pm CEST / 10am EDT / 7am PDT. Read More

Webinar date:
Co-sponsored by Benching and Bio-Rad
#News

Antibodies
#Antibodies #Antibody discovery workflow #Antibody-based therapeutics #Monoclonal antibodies #Therapeutic Antibodies

Webinar: Innovations and opportunities in the therapeutic antibody market

Join DDW for this free event ‘Where is the opportunity in the therapeutic antibody market?’, which is co-sponsored by Bio-Rad and Benchling. The event will take place on 30 April at 3PM BST / 4pm CEST / 10am EDT / 7am PDT. Read More

Webinar date:
Co-sponsored by Benching and Bio-Rad
#News

#Antibodies #Antibody discovery workflow #Antibody-based therapeutics #Monoclonal antibodies #Therapeutic Antibodies

Where is the opportunity in the therapeutic antibody market?

Join DDW for this free event ‘Where is the opportunity in the therapeutic antibody market?’, which is co-sponsored by Bio-Rad and Benchling. The event will take place on 30 April at 3PM BST / 4pm CEST / 10am EDT / 7am PDT. Read More

Webinar date:
Co-sponsored by Benching and Bio-Rad
#News

Monoclonal antibodies
#Antibody discovery workflow #Antibody-based therapeutics #App note #Biologics #Monoclonal antibodies

App Note: How Merck creates developability profiles for mAbs

Download this new Application Note to discover how the Protein Sciences group at Merck & Co. builds developability profiles for their monoclonal antibody variants. Get an in-depth explanation of the experiments they set up to obtain parameters that help them decide which candidates have the best potential to reach… Read More

#News